Abstract
Once-daily indacaterol/mometasone furoate (IND/MF) is an inhaled long-acting β2-agonist/inhaled corticosteroid (LABA/ICS), recently approved for maintenance treatment of asthma. Pharmacokinetics of IND and MF after once-daily oral inhalation of IND/MF low- (150/80 μg), medium- (150/160 μg) and high-dose (150/320 μg) for 14 days were assessed in healthy Chinese volunteers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
